AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 37582633
Drug: No recreational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No recreational drug use (negative test)
Trial: 37582730
Drug: Coronary catheterization
RxNorm normalized name: Glebionis coronaria whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coronary catheterization (CC) procedure once
Trial: 37582730
Drug: Coronary catheterization
RxNorm normalized name: Glebionis coronaria whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coronary catheterization (CC) procedure twice
Trial: 37582730
Drug: Coronary catheterization
RxNorm normalized name: Glebionis coronaria whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coronary catheterization (CC) procedure
Trial: 37582952
Drug: Elranatamab (subcutaneous,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elranatamab (subcutaneous, once weekly after two step-up priming doses)
Trial: 37582952
Drug: Elranatamab (biweekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elranatamab (biweekly dosing after six cycles for persistent responders)
Trial: 37582952
Drug: Elranatamab (overall
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elranatamab (overall treatment)
Trial: 37582952
Drug: Elranatamab (biweekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elranatamab (biweekly dosing)
Trial: 37584207
Drug: Dual-therapy sirolimus-eluting
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dual-therapy sirolimus-eluting and CD34 antibody-coated COMBO stent (DTS)
Trial: 37584254
Drug: RSV 10
RxNorm normalized name: RSV-IGIV
DrugBank: Respigam (DB17765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RSV 10 mg/AML 5 mg
Trial: 37584254
Drug: RSV 20
RxNorm normalized name: RSV-IGIV
DrugBank: Respigam (DB17765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RSV 20 mg/AML 5 mg
Trial: 37584254
Drug: ATV 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATV 20 mg/AML 5 mg
Trial: 37584292
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment for refractory chronic GVHD
Trial: 37584344
Drug: Standard vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard vaccine
Trial: 37584609
Drug: Insulin resistance
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin resistance individuals
Trial: 37584898
Drug: Triptorelin pamoate
RxNorm normalized name: Triptorelin Pamoate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triptorelin pamoate 15 mg administered on day 1 and at months 3, 6, and 9
Trial: 37585243
Drug: Self-administered web-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administered web-based dietary recall
Trial: 37585243
Drug: Interviewer-administered 24-hour
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interviewer-administered 24-hour dietary recall
Trial: 37585569
Drug: Two-phased telehealth
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-phased telehealth model for PTSD treatment
Trial: 37585628
Drug: GNT0003 (gene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GNT0003 (gene therapy) - higher dose
Trial: 37585628
Drug: GNT0003 (gene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GNT0003 (gene therapy) - lower dose
Trial: 37585628
Drug: GNT0003 (gene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GNT0003 (gene therapy)
Trial: 37585627
Drug: Endocrine therapy
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endocrine therapy alone (no radiotherapy)
Trial: 37586052
Drug: Vibegron treatment,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vibegron treatment, dosage and duration not specified
Trial: 37586317
Drug: TAEST16001 T
RxNorm normalized name: T-5224
DrugBank: T-5224 (DB05998)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAEST16001 T cell therapy after dose-reduced lymphodepletion with cyclophosphamide (15 mg/kg/day × 3 days) and fludarabine (20 mg/m2/day)
Trial: 37586350
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment (n = 40)
Trial: 37586350
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment (n = 26)
Trial: 37586475
Drug: Mepolizumab (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mepolizumab (100 mg subcutaneously every 4 weeks for 52 weeks)
Trial: 37586560
Drug: Bi-weekly home
RxNorm normalized name: selinexor
DrugBank: Selinexor (DB11942)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Bi-weekly home food delivery from the local food bank
Trial: 37586560
Drug: Bi-weekly financial
RxNorm normalized name: selinexor
DrugBank: Selinexor (DB11942)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Bi-weekly financial assistance with healthy food access navigation
Trial: 37586845
Drug: Colchicine treatment
RxNorm normalized name: Colchicine
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colchicine treatment 0.5 mg two times per day
Trial: 37586862
Drug: biomodulation protocol
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: biomodulation protocol (cryobiomodulation, photobiomodulation, electrobiomodulation) administered during the first 6 weeks after surgery
Trial: 37586906
Drug: Intramuscular fat
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular fat fraction (IMFF) ≥ 15%
Trial: 37587184
Drug: IV caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV caffeine 20 mg/kg followed by up to two daily doses of 5 mg/kg
Trial: 37587184
Drug: IV caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV caffeine 20 mg/kg followed by up to two daily doses of 10 mg/kg
Trial: 37587323
Drug: HCV cure
RxNorm normalized name: Cocci-Cure C for Calves
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCV cure (DAAs treatment)
Trial: 37587492
Drug: Intravenous arginine
RxNorm normalized name: Arginine
DrugBank: Arginine (DB00125)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous arginine therapy (200 mg/kg loading dose, max 20 g; followed by 100 mg/kg three times a day, max 10 g)
Trial: 37587492
Drug: Placebo (normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (normal saline loading dose followed by normal saline three times a day)
Trial: 37587502
Drug: FLYSYN (Fc-optimized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FLYSYN (Fc-optimized antibody directed to FLT3/CD135), administered intravenously at different dose levels (0.5 mg/m² in cohort 1-5)
Trial: 37587502
Drug: FLYSYN (Fc-optimized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FLYSYN (Fc-optimized antibody directed to FLT3/CD135)
Trial: 37587552
Drug: electronically delivered
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: electronically delivered Cognitive Behavioral Therapy (e-CBT) program
Trial: 37587580
Drug: Dual antiplatelet
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antiplatelet therapy (DAPT) with aspirin and ticagrelor
Trial: 37587591
Drug: Low-dose colchicine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose colchicine (0.6 mg daily) with ticagrelor or prasugrel
Trial: 37587734
Drug: Ultrasound-guided selective
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided selective supraclavicular nerve block with 0.1 mL/kg of 0.5% ropivacaine (SSCNB group)
Trial: 37588266
Drug: Weight-adjusted dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight-adjusted dosing of fibrinogen concentrate
Trial: 37588266
Drug: Empiric dosing
RxNorm normalized name: aspirin / codeine phosphate Oral Tablet [Empirin with Codeine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empiric dosing of fibrinogen concentrate
Trial: 37588667
Drug: Daily electronically
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily electronically recorded patient-reported outcomes (ePROs) on the presence of MG symptoms, level of symptom severity (MG-ADL), and exacerbation status.
Trial: 37588667
Drug: Self-reported MG-ADL
RxNorm normalized name: Adlyxin
DrugBank: Lixisenatide (DB09265)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Self-reported MG-ADL scores during exacerbation periods.
Trial: 37588667
Drug: Self-reported MG-ADL
RxNorm normalized name: Adlyxin
DrugBank: Lixisenatide (DB09265)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Self-reported MG-ADL scores during non-exacerbation periods.
Trial: 37588667
Drug: Dynamic changes
RxNorm normalized name: water
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dynamic changes in day-to-day symptom reporting and severity, daily step counts, clinical characteristics.
Trial: 37589641
Drug: Multiphase SCS
RxNorm normalized name: SC 41930
DrugBank: SC 41930 (DB17101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiphase SCS therapy A (approximately 600-1500 Hz)
Trial: 37589641
Drug: Multiphase SCS
RxNorm normalized name: SC 41930
DrugBank: SC 41930 (DB17101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiphase SCS therapy B (approximately 300-600 Hz)
Trial: 37589641
Drug: Commercial SCS
RxNorm normalized name: SC 41930
DrugBank: SC 41930 (DB17101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commercial SCS therapy
Trial: 37589639
Drug: Autologous IFNγ-stimulated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous IFNγ-stimulated MSC(M) injection into submandibular gland
Trial: 37589639
Drug: Autologous IFNγ-stimulated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous IFNγ-stimulated MSC(M) injection
Trial: 37589748
Drug: Mandibular advancement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mandibular advancement device (MAD) therapy
Trial: 37589748
Drug: MAD therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAD therapy
Trial: 37589932
Drug: IPL +
RxNorm normalized name: IPL-344
DrugBank: IPL-344 (DB16958)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IPL + DQS therapy
Trial: 37589932
Drug: IPL therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IPL therapy
Trial: 37590001
Drug: Anticancer agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticancer agents targeting AMPK
Trial: 37591292
Drug: Nefecon (targeted-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefecon (targeted-release formulation of budesonide)
Trial: 37591293
Drug: Cemiplimab 350
RxNorm normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cemiplimab 350 mg every 3 weeks for up to 108 weeks
Trial: 37591293
Drug: Cemiplimab plus
RxNorm normalized name: cemiplimab
DrugBank: Cemiplimab (DB14707)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cemiplimab plus chemotherapy (as second-line therapy)
Trial: 37591308
Drug: Treatment concepts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment concepts converting DMD to BMD phenotype
Trial: 37591454
Drug: 7-item Satisfaction
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 7-item Satisfaction with Treatment
Trial: 37591633
Drug: Tocilizumab (280
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocilizumab (280 mg single dose)
Trial: 37591655
Drug: 4.2% sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.2% sodium bicarbonate infusion to target a plasma pH ≥ 7.30
Trial: 37591655
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no sodium bicarbonate infusion)
Trial: 37591655
Drug: 4.2% sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.2% sodium bicarbonate infusion
Trial: 37592092
Drug: Bosutinib 300
RxNorm normalized name: Bosutinib
DrugBank: Bosutinib (DB06616)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Bosutinib 300 mg QD (step-in dosing)
Trial: 37592092
Drug: Bosutinib 400
RxNorm normalized name: bosutinib 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bosutinib 400 mg QD (approved first-line dose)
Trial: 37592092
Drug: Bosutinib 500
RxNorm normalized name: bosutinib 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bosutinib 500 mg QD (approved later-line dose)
Trial: 37592104
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ipilimumab and nivolumab
Trial: 37592217
Drug: Standard speech
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard speech therapy remediation
Trial: 37592263
Drug: Inhalation technique
RxNorm normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation technique errors 'Breathe in', 'Hold breath', 'Breathe out calmly after inhalation'
Trial: 37592263
Drug: Inhalation technique
RxNorm normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation technique errors 'Preparation', 'Hold inhaler in correct position during inhalation', 'Breathe in'
Trial: 37592263
Drug: Overall inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall inhalation technique errors
Trial: 37592263
Drug: Specific combinations
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific combinations of inhalation technique errors
Trial: 37592263
Drug: Increasing inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increasing inhalation technique error count
Trial: 37592358
Drug: Music intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Music intervention (twice daily for three days, at least 30 min per session)
Trial: 37592403
Drug: 2.5 mL
RxNorm normalized name: syringe, disposable, 2.5 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mL of 40% ethanol per kg body weight via a nasogastric tube
Trial: 37592860
Drug: Transcranial direct
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcranial direct current stimulation (tDCS) combined with language therapy
Trial: 37592860
Drug: Language treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Language treatment alone (Control)
Trial: 37593221
Drug: sintilimab plus
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sintilimab plus bevacizumab (200 mg and 7.5 mg/kg respectively, intravenously every 3 weeks)
Trial: 37593227
Drug: AK112 combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AK112 combined with pemetrexed (500 mg/m2) in cohort 1 (previously untreated)
Trial: 37593227
Drug: AK112 combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AK112 combined with chemotherapy in cohort 2 (EGFR-functional mutation)
Trial: 37593227
Drug: AK112 combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AK112 combined with chemotherapy in cohort 3 (failed prior systemic treatments)
Trial: 37593752
Drug: feladilimab (anti-ICOS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: feladilimab (anti-ICOS mAb) + pembrolizumab (PD-1 inhibitor)
Trial: 37593838
Drug: DWP16001 (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DWP16001 (2 mg)
Trial: 37593838
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of DWP16001 and phentermine
Trial: 37593881
Drug: Vimseltinib 30
RxNorm normalized name: vimseltinib 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vimseltinib 30 mg twice weekly for up to 24 weeks
Trial: 37594044
Drug: Mirikizumab 200
RxNorm normalized name: Mirikizumab
DrugBank: Mirikizumab (DB14910)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirikizumab 200 mg subcutaneous every 4 or 12 weeks through week 52
Trial: 37594769
Drug: Algorithmic approach
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Algorithmic approach to ventilator withdrawal; details on dosage and duration not available.
Trial: 37594769
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care for ventilator withdrawal; details on dosage and duration not available.
Trial: 37594946
Drug: Play-based, parent-delivered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Play-based, parent-delivered intervention focusing on regaining pre-treatment mobility and midline crossing until 7 weeks post-treatment, individualized from 7 weeks to 6 months post-treatment.
Trial: 37595103
Drug: Baloxavir marboxil
RxNorm normalized name: Baloxavir Marboxil
DrugBank: Baloxavir marboxil (DB13997)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Baloxavir marboxil (single-dose)
Trial: 37595103
Drug: Oseltamivir (twice-daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oseltamivir (twice-daily for 5 days)
Trial: 37596281
Drug: Intranasal adenoviral
RxNorm normalized name: COVID-19 VACCINE ADENOVIRUS-26
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal adenoviral vectored SARS-CoV-2 vaccine (BBV154)
Trial: 37596281
Drug: Licensed intramuscular
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Licensed intramuscular vaccine, Covaxin
Trial: 37596280
Drug: CoVac-1 (one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CoVac-1 (one subcutaneous dose)
Trial: 37596449
Drug: Cytoreductive surgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) with complete cytoreduction (CC-0)
Trial: 37596658
Drug: carbon suspension
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: carbon suspension
Trial: 37596658
Drug: clip + iodine seed,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: clip + iodine seed, magnetic seed, carbon suspension
Trial: 37597153
Drug: Idecabtagene vicleucel
RxNorm normalized name: idecabtagene vicleucel
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idecabtagene vicleucel (ide-cel) treatment
Trial: 37597159
Drug: Guselkumab (subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guselkumab (subcutaneous 100 mg at weeks 0, 4, and every 8 weeks)
Trial: 37597246
Drug: Binimetinib (45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Binimetinib (45 mg twice daily) plus Panitumumab (6 mg/kg every 2 weeks)
Trial: 37597326
Drug: Adjunctive brivaracetam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive brivaracetam (BRV) treatment
Trial: 37597523
Drug: Levonorgestrel 1.5
RxNorm normalized name: levonorgestrel 1.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levonorgestrel 1.5 mg plus piroxicam 40 mg
Trial: 37597523
Drug: Levonorgestrel 1.5
RxNorm normalized name: levonorgestrel 1.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levonorgestrel 1.5 mg plus placebo
Trial: 37597969
Drug: 9 mg
RxNorm normalized name: fiber 469 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9 mg BI 1015550
Trial: 37597969
Drug: 18 mg
RxNorm normalized name: niacin 18 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18 mg BI 1015550
Trial: 37597969
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (9 mg, 18 mg, placebo)
Trial: 37598795
Drug: Ferric carboxymaltose
RxNorm normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ferric carboxymaltose as treatment for heart failure with iron deficiency
Trial: 37598795
Drug: HFrEF therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HFrEF therapy including beta-blocker
Trial: 37598795
Drug: HFrEF therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HFrEF therapy including ARNI
Trial: 37598795
Drug: HFrEF therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HFrEF therapy including MRA
Trial: 37599908
Drug: Parsaclisib 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parsaclisib 2.5 mg QD (daily dosing group)
Trial: 37599908
Drug: Parsaclisib 20
RxNorm normalized name: Parsaclisib
DrugBank: Parsaclisib (DB14867)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parsaclisib 20 mg QD for 8 weeks, then either 20 mg once-weekly or 2.5 mg QD
Trial: 37600550
Drug: Quercetin aglycone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quercetin aglycone 250 mg
Trial: 37600550
Drug: Quercetin aglycone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quercetin aglycone 500 mg
Trial: 37600550
Drug: Quercetin aglycone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quercetin aglycone 1000 mg
Trial: 37600800
Drug: 1/10 dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1/10 dose of Sputnik V vaccine
Trial: 37600800
Drug: 1/5 dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1/5 dose of Sputnik V vaccine
Trial: 37600876
Drug: Hyperinsulinemic-normoglycemic clamp
RxNorm normalized name: CLAMP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperinsulinemic-normoglycemic clamp (HNC) initiated by infusing insulin at 2 mU/kg/min and administering dextrose to maintain normoglycemia (4.0-6.0 mmol/L).
Trial: 37600959
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of all three tests (PSE, ANT, CFF)